Only a minority of patients referred for elective coronary artery bypass surgery have risk factors diagnosed and treated according to established guidelines
Free accessResearch articleFirst published online June, 2007
Only a minority of patients referred for elective coronary artery bypass surgery have risk factors diagnosed and treated according to established guidelines
Patients deserve to be medically optimised for treatment of metabolic risk factors and hypertension before referral for elective coronary artery bypass grafting (CABG). We describe here a prospective study of 347 consecutive patients referred for elective CABG. An oral glucose tolerance test (OGTT) was performed and metabolic risk factors and hypertension were determined pre-operatively. Compliance to treatment guidelines was calculated.
From the total of 347 patients, 80 patients (23%) had known and 66 (19%) had previously unknown diabetes. Dysglycaemia (that is, diabetes and pre-diabetes) was found in 194 (73%) of the 267 patients without known diabetes. Among patients with dysglycaemia, 111/274 (41%) received one antihypertensive medication, or none, and blood pressure guidelines were met in 39/274 (14%); statins were being taken by 206 (75%; average dose 23 mg simvastatin) and low-density lipoprotein (LDL)-cholesterol guidelines were met in 43 (16%).
In conclusion, diabetes diagnosis and titration of risk factor treatment to guidelines is inadequate even in elective CABG patients. A pre-admission OGTT affords an opportunity to improve care significantly.
1. Norhammar A, Malmberg K, Diderholm E. et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revas-cularization. J Am Coll Cardiol2004;43:585–91.
2.
2. Norhammar A, Tenerz A, Nilsson G. et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet2002;359:2140–4.
3.
3. Anderson RE, Klerdal K, Ivert T, Hammar N, Barr G, Owall A.Are even impaired fasting blood glucose levels preoperatively associated with increased mortality after CABG surgery?Eur Heart J2005;26:1513–18.
4.
4. Lauruschkat AH, Arnrich B, Albert AA. et al. Prevalence and risks of undiagnosed diabetes mellitus in patients undergoing coronary artery bypass grafting. Circulation2005;112:2397–402.
5.
5. Rydén L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J2007;28:88–136.
6.
6. The DECODE study group.Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. European Diabetes Epidemiology Group. Lancet1999;354:617–21.
7.
7. Blake DR, Meigs JB, Muller DC, Najjar SS, Andres R, Nathan DM.Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. Diabetes2004;53:2095–100.
8.
8. Leiter LA, Ceriello A, Davidson JA, Hanefeld M, Monnier L, Owens DR.Postprandial glucose regulation: New data and new implications. Clin Ther2005;27(suppl 2):42–56.
9.
9. Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC.AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. J Am Coll Cardiol2006;47:2130–9.
10.
10. Haffner S.Rationale for new American Diabetes Association Guidelines: are national cholesterol education program goals adequate for the patient with diabetes mellitus?Am J Cardiol2005;96(suppl 4A):33–6.
11.
11. Muhlestein JB, Anderson JL, Horne BD. et al. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J2003;146:351–8.
12.
12. Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Rydén L.Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J2004;25:1990–7.
13.
13. Scognamiglio R, Negut C, De Kreutzenberg SV, Tiengo A, Avogaro A.Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation2005;112:179–84.
14.
14. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O.Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med2003;348:383–93.
15.
15. Port SC, Goodarzi MO, Boyle NG, Jennrich RI.Blood glucose: a strong risk factor for mortality in nondiabetic patients with cardiovascular disease. Am Heart J2005;150:209–14.
16.
16. Abuissa H, Jones PG, Marso SP, O'Keefe JH.Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol2005;46:821–6.
17.
17. Ingelfinger JR, Solomon CG.Angiotensin-converting-enzyme inhibitors for impaired glucose tolerance—is there still hope?N Engl J Med2006;355:1608–10.
18.
18. Shepherd J, Barter P, Carmena, Deedwania P, Fruchart J-C.Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study. Diabetes Care2006;29:1220–6.
19.
19. Clark LL, Ikonomidis JS, Crawford FA. et al. Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg2006;131:679–85.
20.
20. Fonarow GC, Wright RS, Spencer FA. et al. Effects of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol2005;96:611–16.
21.
21. Lazar HL.Should all patients receive statins before cardiac surgery: Are more data necessary?J Thorac Cardiovasc Surg2006;131:520–2.
22.
22. Heart Protection Study Collaborative Group.MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360:7–22.
23.
23. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E.Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol2006;48:438–45.
24.
24. Collard CD, Body SC, Shernan SK, Wang S, Mangano DT.Multicenter Study of Perioperative Ischemia (MCSPI) Research Group. Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg2006;132:392–400.
25.
25. Saydah SH, Fradkin J, Cowie CC.Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA2004;291:335–42.
